ICI, such as monoclonal antibodies blocking the interaction of PD-1 with its ligand PD-L1, have revolutionized cancer treatment by reinvigorating functionally-exhausted T cells within the TME (50, 51). The gene discussed is PDCD1; the disease is cancer.